Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

187
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
187
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

669
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
669
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.1K
Liver Physiology01:30

Liver Physiology

1.6K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

10
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
10
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.

Diabetes, obesity & metabolism·2020
Same author

Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials.

Gastroenterology clinics of North America·2020
Same author

Enteral Access and Associated Complications.

Gastroenterology clinics of North America·2018
Same author

A nutrition strategy for obese ICU patients with special consideration for the reference of protein.

Clinical nutrition ESPEN·2017
Same author

Preseason Perceived Physical Capability and Previous Injury.

Journal of athletic training·2015
Same author

A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.

Clinical drug investigation·2014

Related Experiment Video

Updated: Oct 4, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice.

Sherwyn Schwartz1, Jean Lucas2, Mark H DeLegge3

  • 1Evolution Research Group, San Antonio, TX, USA.

Touchreviews in Endocrinology
|February 4, 2022
PubMed
Summary

Non-alcoholic steatohepatitis (NASH) is a growing global health issue. Primary care physicians and endocrinologists are crucial for NASH patient care and clinical research due to associated metabolic conditions.

Keywords:
Non-alcoholic steatohepatitisdiseasemetabolictype 2 diabetes mellitus

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

6.8K

Related Experiment Videos

Last Updated: Oct 4, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

6.8K

Area of Science:

  • Hepatology and Endocrinology
  • Metabolic Disease Research

Background:

  • Non-alcoholic steatohepatitis (NASH) is a prevalent global liver disease with significant comorbidities.
  • Currently, no approved NASH treatments exist outside India, despite numerous drugs in clinical development.
  • NASH is strongly linked to metabolic conditions like type 2 diabetes, obesity, and hyperlipidemia.

Purpose of the Study:

  • To review the literature and analyze patient claims data regarding NASH care.
  • To assess the role of primary care physicians and endocrinologists in NASH management and research.
  • To highlight the importance of these specialists in the evolving NASH landscape.

Main Methods:

  • Literature review on NASH diagnosis, treatment, and clinical trials.
  • Analysis of IQVIA's proprietary patient claims database (diagnosis codes, encounters, treatments).
  • Assessment of the intersection between metabolic comorbidities and NASH.

Main Results:

  • Primary care physicians and internists encounter numerous NASH-associated metabolic diseases.
  • Endocrinologists manage conditions frequently comorbid with NASH.
  • Patient claims data confirm the pivotal role of primary care and endocrinology in NASH care and research.

Conclusions:

  • Primary care providers and endocrinologists are essential in identifying and managing NASH patients.
  • These specialists are critical for recruiting subjects for NASH clinical trials.
  • Evolving practice guidelines underscore the importance of integrated care for NASH.